RxDoctor Payments Data

Ijeoma Ajufo, MD

Psychiatry · San Antonio, TXNPI 1902216427

Payments from drug & device makers

$1,483in general payments, 2019–2025

Across 56 payments — averaging $26.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$485
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$423
  • Supernus Pharmaceuticals, Inc.$140
  • Almatica Pharma LLC$130
  • Novo Nordisk$84
  • Teva Pharmaceuticals USA, Inc.$68
  • plus $153 from 6 others

What the payments were for

  • Food & beverage$1,44497%
  • Education$393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,483 in reported general payments places this provider in the 70th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$34,129
Medicare patients
48
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Methylphenidate ErMethylphenidate Hcl18$1,877
Clonazepam69$698
Gabapentin39$614
Quetiapine Fumarate30$585
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine24$564
Duloxetine Hcl26$536
Bupropion XlBupropion Hcl17$530
Trazodone Hcl35$324
Mirtazapine19$320
Sertraline Hcl30$266
Escitalopram Oxalate18$266
Lamotrigine13$261
Divalproex Sodium15$256
Zolpidem Tartrate31$213
Bupropion Hcl SrBupropion Hcl16$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$130$26630 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →